Dapagliflozin in Pulmonary Arterial Hypertension

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 1, 2023

Primary Completion Date

June 30, 2024

Study Completion Date

September 30, 2024

Conditions

Pulmonary Arterial HypertensionChronic Thromboembolic Pulmonary Hypertension

Interventions

DRUG

Dapagliflozin 10 MG [Farxiga]

Dapagliflozin 10 mg given once daily for three months

DRUG

Placebo

Matching placebo

Trial Locations (1)

RECRUITING

Rigshospitalet, Copenhagen

All Listed Sponsors

lead

Mads Ersbøll

OTHER